Biotech Values

[DewDiligence]

ADXS +6% on planned start of phase-1/2 trial of ADXS-HPV ± AZN’s MEDI4736:

http://finance.yahoo.com/news/advaxis-announces-fda-acceptance-investigational-123000628.html

Advaxis, Inc. announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The trial is expected to begin patient enrollment in early 2015.

The companies announced their clinical-trial collaboration in Jul 2014 (http://www.astrazeneca.com/Media/Press-releases/Article/20140721--tba ).